Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

HBV in 2016

Global and immunotherapeutic insights into hepatitis B

Nature Reviews Gastroenterology & Hepatology volume 14, pages 71–72 (2017)Cite this article

Subjects

The burden of HBV infection remains high and new strategies to improve HBV vaccination and therapy are needed. Key research in 2016 highlights the efficacy of current approaches and proposes new concepts for some of the immunological defects that need to be overcome for HBV functional cure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Presentation of HBV antigens by myeloid cells or hepatocytes triggers HBV-specific T-cell deletion or inactivation.

References

  1. Stanaway, J. D. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388, 1081–1088 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Chang, M. H. et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 151, 472–480.e1 (2016).

    Article  CAS  PubMed  Google Scholar 

  3. Pan, C. Q. et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N. Engl. J. Med. 374, 2324–2334 (2016).

    Article  CAS  PubMed  Google Scholar 

  4. Lok, A. S. et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J. Hepatol. 65, 509–516 (2016).

    Article  CAS  PubMed  Google Scholar 

  5. Tian, Y., Kuo, C.-F., Akbari, O. & Ou, J.-H. J. Maternal-derived hepatitis B virus e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission. Immunity 44, 1204–1214 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Zeng, Z. et al. Interferon-γ facilitates hepatic antiviral T cell retention for the maintenance of liver-induced systemic tolerance. J. Exp. Med. 213, 1079–1093 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hong, M. et al. Trained immunity in newborn infants of HBV-infected mothers. Nat. Commun. 6, 6558 (2015).

    Article  Google Scholar 

  8. Mason, W. S. et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology 151, 986–998.e4 (2016).

    Article  CAS  PubMed  Google Scholar 

  9. Schurich, A. et al. Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Rep. 16, 1243–1252 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zhang, X. et al. In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection. J. Clin. Invest. 126, 1079–1092 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

M.K.M. is supported by a Wellcome Trust Senior Investigator Award and a Medical Research Council project grant. A.B. is supported by a Singapore Translational Research (STaR) Investigator Award (NMRC/STaR/013/2012).

Author information

Authors and Affiliations

  1. Division of Infection and Immunity, University College London, Rayne Institute, 5 University Street, London, WC1E 6JF, UK

    Mala K. Maini

  2. Emerging Infectious Diseases Program, Duke-NUS Graduate Medical School, 8 College Road, 169857, Singapore; and at the Singapore Immunology Network (SigN) 8A Biomedical Grove, 138648, Singapore.,

    Antonio Bertoletti

  3. and at the Singapore Immunology Network (SigN) 8A Biomedical Grove, 138648, Singapore.,

    Antonio Bertoletti

Authors
  1. Mala K. Maini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Bertoletti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mala K. Maini.

Ethics declarations

Competing interests

M.K.M. lab has received research funding from Gilead and Roche, and has served as a consultant and on advisory boards for BMS, Galapagos, Gilead, ITS, Medimmune, Roche and Transgene. A.B. collaborates and receives research support from Gilead. He acted as a consultant and served on the advisory boards of Abivax, Gilead, Humabs BioMed, Jansseen-Cilag, Medimmune. A.B. is also a co-founder of LION TCR, a biotech company developing T-cell receptors for treatment of virus-related cancers and chronic viral diseases.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maini, M., Bertoletti, A. Global and immunotherapeutic insights into hepatitis B. Nat Rev Gastroenterol Hepatol 14, 71–72 (2017). https://doi.org/10.1038/nrgastro.2016.196

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2016.196

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing